SCHEMBL21238086

SCHEMBL21238086

O=C1C2CCC[C@H]1CN(Cc1ccccc1)C2

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.51
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
S1PR1 P21453 1/20 0.49
S1PR5 Q9H228 1/20 0.49
SIGMAR1 Q99720 1/20 0.48
ACHE P22303 1/20 0.47
CCR3 P51677 1/20 0.46
MEN1 O00255 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21220647 1.00 FUCA1 (0.51) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL2852290 1.00 FUCA1 (0.51) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL14529645 0.96 ALDH1A1 (0.53) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL30875889 0.93 FUCA1 (0.55) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19518531 0.93 FUCA1 (0.55) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL20417932 0.93 FUCA1 (0.55) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL17560348 0.93 FUCA1 (0.55) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL1514852 0.93 FUCA1 (0.55) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
Ethylene SCHEMBL2678737 0.89 FUCA1 (0.51) FUCA1ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL2962712 0.89 FUCA1 (0.58) FUCA1S1PR1S1PR5SIGMAR1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021026375-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF PAIN ALKERMES, INC. (US) 2021-02-11 WO disclosed
WO-2019152946-A1 COMPOUNDS FOR THE TREATMENT OF PAIN ALKERMES, INC. (US) 2019-08-08 WO disclosed